SCHEMBL2642265

SCHEMBL2642265

Cn1ccc(Nc2ncnc3ccccc23)n1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GCK P35557 15/20 0.62
EGFR P00533 2/20 0.54
ABCG2 Q9UNQ0 2/20 0.54
DAPK3 O43293 1/20 0.54
MAP4K4 O95819 1/20 0.54
ABL1 P00519 1/20 0.54
ERBB2 P04626 1/20 0.54
PIM1 P11309 1/20 0.54
PRKACA P17612 1/20 0.54
LTK P29376 1/20 0.54
MAPK8 P45983 1/20 0.54
CSNK1A1 P48729 1/20 0.54
RPS6KA3 P51812 1/20 0.54
LIMK1 P53667 1/20 0.54
MAP2K1 Q02750 1/20 0.54
ACVR1 Q04771 1/20 0.54
TYRO3 Q06418 1/20 0.54
MAP4K2 Q12851 1/20 0.54
ROCK1 Q13464 1/20 0.54
DYRK1A Q13627 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2642264 0.81 GCK (0.60) GCKEGFRERBB2
SCHEMBL12095668 0.78 LMNA (0.53) GCKEGFRABCG2DAPK3MAP4K4
SCHEMBL2660088 0.77 GCK (0.75) GCKEGFRNPC1RAB9A
SCHEMBL8976752 0.77 EGFR (0.78) EGFRABCG2DAPK3MAP4K4ABL1
SCHEMBL2642156 0.76 GCK (0.68) GCKEGFR
SCHEMBL2642071 0.75 GCK (0.67) GCKEGFR
SCHEMBL2642371 0.74 GCK (1.00) GCK
SCHEMBL6019212 0.74 ABCG2 (0.45) GCKEGFRABCG2DAPK3MAP4K4
SCHEMBL2642032 0.73 GCK (0.75) GCK
SCHEMBL6831353 0.73 EGFR (0.62) EGFRABCG2DAPK3MAP4K4ABL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7687502-B2 Substituted quinazoline or pyridopyrimidine derivative BANYU PHARMACEUTICAL CO., LTD. (JP) 2010-03-30 US claimed
US-20080032996-A1 Substituted Quinazoline or Pyridopyrimidine Derivative MSD K.K. (JP) 2008-02-07 US claimed
EP-1734040-A1 SUBSTITUTED QUINAZOLINE OR PYRIDOPYRIMIDINE DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2006-12-20 EP claimed
US-7687502-B2 Substituted quinazoline or pyridopyrimidine derivative BANYU PHARMACEUTICAL CO., LTD. (JP) 2010-03-30 US disclosed
US-20080032996-A1 Substituted Quinazoline or Pyridopyrimidine Derivative MSD K.K. (JP) 2008-02-07 US disclosed
EP-1734040-A1 SUBSTITUTED QUINAZOLINE OR PYRIDOPYRIMIDINE DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2006-12-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080032996-A1 Substituted Quinazoline or Pyridopyrimidine Derivative GCK, GCKR, PDXK GCK 1/4885EGFR 3484/4885ABCG2 383/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.